Navigation Links
Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
Date:6/28/2012

(PRWEB) June 28, 2012

ProImmune's Immune Formulation 200® is able to potentiate Glutathione synthesis via the Pleiotropic Paradox, which utilizes the pleiotropic delivery system of the disulfide bond--L-Cystine--to carry L-Cysteine safely to cells,. Upon contact with epithelial cells, the L-Cystine is decoupled by the substrate specific enzyme thioltransferase, allowing L-Cysteine safely into cells to enter into the Glutathione Synthesis chain.

Dr. Albert Crum, a Harvard-trained scientist and CEO of The ProImmune Company, LLC, Rhinebeck (NY) is the inventor of Patent RE42,645E/RE39,734 and its Immune Formulation 200®. University research using Immune Formulation 200® provided by The ProImmune Company, LLC, has demonstrated that this novel Glutathione precursor’s immune support effects are unexpectedly wide-ranging.

The coupling of a thiol-disulfide compound is another safe physiological carrier system for L-Cysteine, because it holds the high oxidizability of L-Cysteine in abeyance ("on hold") until it is delivered to the intracellular milieu.

Metaphorically speaking, the Glutathione pathway of Immune Formulation 200® activates the immune system like a city power grid station which ignites or electrifies a city's lights. The Dietary Supplement Immune Formulation 200® is a strong support for the immune system in multiple ways.

Immune Formulation 200® works physiologically, both to raise bodily Glutathione levels and to activate Nrf2, while offering an inherently natural sweet taste without carbohydrates. Immune Formulation 200® (“F1”), a dietary supplement, is the patented precursor for the intracellular synthesis of Glutathione.

Specifically, research on Immune Formulation 200® provided by The ProImmune Company, L.L.C., has been conducted over several years by a team at Drew University of Medicine & Science, Los Angeles (CA). Other universities such as UCLA, University of California (Irvine), Los Angeles Biomedical Research Institute (Torrance CA), and University of Texas Southwestern (Dallas) are included among those conducting the basic research on Immune Formulation 200®. Research results began being published in 2008. Research studies of Immune Formulation 200® have pointed to the interrelationship between Glutathione repletion and activation of gene Nrf2.

Immune Formulation 200® is winning international consumer favor--for the value of its diversified immunological support and for its naturally sweet taste.

The study which associated Immune Formulation 200® with the activation of Nrf2 was supported by NIH-NCCR Accelerating Excellence in Translation Science Grant (U54 RR026138) and NIH-NIMHDP20MD00182.

© 2012 The ProImmune Company LLC

Read the full story at http://www.prweb.com/releases/2012/6/prweb9653539.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
2. Study improves understanding of surface molecules in controlling size of gold nanoparticles
3. Nanoparticles found in moon glass bubbles explain weird lunar soil behavior
4. Nanoparticles seen as artificial atoms
5. Exotic particles, chilled and trapped, form giant matter wave
6. A milestone in nanoparticle research: Nanoparticle test handbook sets the standards
7. Genesis Biopharma Mentioned Favorably in BioMedReports Article
8. Light touch keeps a grip on delicate nanoparticles
9. New technique uses electrons to map nanoparticle atomic structures
10. New measuring techniques can improve efficiency, safety of nanoparticles
11. Metal nanoparticles shine with customizable color
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
(Date:9/15/2017)... Diego, CA (PRWEB) , ... September 15, 2017 ... ... Grolltex, has recently closed what it calls an ‘Internal Seed B’ round of ... the company’s stock and was completed using a ‘SAFE’ documentation structure at a ...
(Date:9/14/2017)... ... September 14, 2017 , ... DrugDev ... biotech at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. ... most progressive clinical research leaders for best practice case studies, keynote presentations, lively ...
(Date:9/14/2017)... ... September 14, 2017 , ... Boston Strategic ... experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide ... 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. ...
(Date:9/14/2017)... ... 2017 , ... One of the world’s largest World Marrow Donor Day events ... that day, the GenCure Marrow Donor Program will be signing up potential donors for ... San Antonio. , The registration tables will be staffed by employees from all the ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):